Jun 02, 2020
Surgical Information Sciences Announces CE Mark for its DBS Visualization Guiding System
Sep 11, 2019
The global Tourette's syndrome drugs market at a CAGR of almost 5% during the forecast period
Jun 25, 2019
Global Deep Brain Stimulation (DBS) Devices Market Outlook 2019-2024: Novel Applications Bode Tremendous Prospects
May 06, 2019
New AAN Guideline for Treating Tourette Syndrome and Other Chronic Tic Disorders
Dec 12, 2018
Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome
Aug 14, 2018
Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome
Apr 24, 2018
Boston Scientific Announces Positive Late-Breaking Data From The INTREPID Study
Apr 09, 2018
Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program
Feb 07, 2018
Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected
Dec 04, 2017
Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program
Dec 04, 2017
Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program
Nov 28, 2017
Abide Therapeutics Reports Positive Topline Data from Phase 1b Study of ABX-1431 in Tourette Syndrome
Nov 21, 2017
Therapix Biosciences Spotlighted in Financial and Trade Media Outlets
Oct 25, 2017
Neurocrine Initiates Phase IIb Clinical Study of Once-daily INGREZZA® in Children and Adolescents with Tourette Syndrome
Oct 23, 2017
Neurocrine Granted FDA Orphan Drug Designation for Valbenazine for the Treatment of Pediatric Patients With Tourette Syndrome
Oct 06, 2017
Therapix Signs Formulation Development and Clinical Manufacturing Agreement with Catalent for THX-TS01